Secondary hyperparathyroidism among Nigerians with chronic kidney disease
- PMID: 30602972
- PMCID: PMC6306980
- DOI: 10.4314/ahs.v18i2.30
Secondary hyperparathyroidism among Nigerians with chronic kidney disease
Abstract
Backround: Secondary hyperparathyroidism (SHPT) is a manifestation of chronic kidney disease mineral bone disorder (CKD-MBD). SHPT is common in patients with chronic kidney disease (CKD) and is associated with significant morbidity and mortality.
Methods: A cross- sectional descriptive study involving 230 patients with CKD.
Results: The mean age of the study population was 44.17±15.24 years. The median intact parathyroid hormone and alkaline phosphatase levels were 96pg/ml (range 4-953pg/ml) and 88 iu/l (range 10-800 iu/l) respectively. The mean (with standard deviation) calcium, serum phosphate, calcium phosphate product and haemoglobin levels were 2.22±0.29mmol/l, 1.8±0.62mmol/l, 3.94±1.42mmol2/l2 and 9.90±1.87g/dl respectively. Majority of patients had advanced CKD with 70.3% of patients in stage G5. The prevalence rates of SHPT, hypocalcaemia, hyperphosphataemia, elevated alkaline phosphatase and elevated calcium phosphate product were 55.2%, 34.8%, 66.1%, 42.2% and 25.2% respectively.Univariate analysis revealed that SHPT was associated with hypocalcaemia, hyperphosphataemia, elevated alkaline phosphatase, proteinuria, anaemia, hypertension, left ventricular hypertrophy and stage of kidney disease; being worse with advancing kidney disease. Independently associated with SHPT were hypocalcaemia (OR=4.84), hyperphosphataemia (OR=3.06), and elevated alkaline phosphatase (OR=2.04).
Conclusion: The prevalence of SHPT in CKD is high, occurs early and is independently associated with hypocalcaemia, hyperphosphataemia and elevated alkaline phosphatase. The prevalence of SHPT also increases with worsening renal function.
Keywords: Secondary hyperparathyroidism; chronic kidney disease; elevated alkaline phosphatase; hyperphosphataemia; hypocalcaemia; intact parathyroid hormone.
Figures




Similar articles
-
Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort.Nephrol Dial Transplant. 2022 Mar 25;37(4):663-672. doi: 10.1093/ndt/gfab184. Nephrol Dial Transplant. 2022. PMID: 34021359
-
Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort.PLoS One. 2018 Jun 18;13(6):e0199140. doi: 10.1371/journal.pone.0199140. eCollection 2018. PLoS One. 2018. PMID: 29912988 Free PMC article.
-
Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.J Manag Care Pharm. 2007 Jun;13(5):397-411. doi: 10.18553/jmcp.2007.13.5.397. J Manag Care Pharm. 2007. PMID: 17605511 Free PMC article. Review.
-
[Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study].Nephrol Ther. 2011 Jul;7(4):229-36. doi: 10.1016/j.nephro.2011.01.008. Epub 2011 Feb 25. Nephrol Ther. 2011. PMID: 21353659 French.
-
Treatment of hyperphosphatemia: the dangers of high PTH levels.Pediatr Nephrol. 2020 Mar;35(3):493-500. doi: 10.1007/s00467-019-04400-w. Epub 2019 Nov 6. Pediatr Nephrol. 2020. PMID: 31696357 Review.
Cited by
-
Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease.Afr Health Sci. 2022 Mar;22(1):344-351. doi: 10.4314/ahs.v22i1.42. Afr Health Sci. 2022. PMID: 36032486 Free PMC article.
-
Risk Factor Analysis and Prediction of Severe Hypocalcemia after Total Parathyroidectomy without Auto-Transplantation in Patients with Secondary Hyperparathyroidism.Int J Endocrinol. 2023 Jan 16;2023:1901697. doi: 10.1155/2023/1901697. eCollection 2023. Int J Endocrinol. 2023. PMID: 36700169 Free PMC article.
-
Influencing factors of cardiac valve calcification (CVC) in patients with chronic kidney disease and the impact of CVC on long-term prognosis: a single-center retrospective study.PeerJ. 2023 Jun 30;11:e15569. doi: 10.7717/peerj.15569. eCollection 2023. PeerJ. 2023. PMID: 37404480 Free PMC article.
-
Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease.Front Endocrinol (Lausanne). 2024 Jun 21;15:1400891. doi: 10.3389/fendo.2024.1400891. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38974573 Free PMC article.
-
Sexuality and other issues in Africa and beyond.Afr Health Sci. 2018 Jun;18(2):i-iii. doi: 10.4314/ahs.v18i2.1. Afr Health Sci. 2018. PMID: 30602976 Free PMC article. No abstract available.
References
-
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD work group, author. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD) Kidney Int. 2009;76(suppl 113):S1–S130. - PubMed
-
- Sarnak MJ, Levey AS. Cardiovascualr disease and chronic renal disease: a new paradigm shift. Am J Kidney Dis. 2000;35:S117–S131. - PubMed
-
- Foley RN, Parfrey PS, Sarnak MJ. Cinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–S119. - PubMed
-
- Silver J. Regulation of parathyroid hormone gene by vitamin D, calcium and phosphate. Kidney intl. 1999;56(suppl73):S2–S7. - PubMed
-
- Khan S. Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease. Am J Med Sci. 2007;333:201–207. PubMed. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical